|
Bieżący numer
Archiwum
Filmy
Artykuły w druku
O czasopiśmie
Suplementy
Rada naukowa
Recenzenci
Bazy indeksacyjne
Prenumerata
Kontakt
Zasady publikacji prac
Opłaty publikacyjne
Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
|
3/2024
vol. 126 Artykuł przeglądowy
Zakrzep żył siatkówki oka - patomechanizmy ze szczególnym uwzględnieniem młodszych pacjentów
Wojciech Zawisza
1
KLINIKA OCZNA 2024, 126, 3: 124-127
Data publikacji online: 2024/10/09
Pobierz cytowanie
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126: 513-518. 2.
Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond) 2011; 25: 981-988. 3.
Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311. 4.
Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77. 5.
Sperduto RD, Hiller R, Chew E, et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 1998; 105: 765-771. 6.
Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol 2000; 11: 462-467. 7.
Lee JY, Yoon YH, Kim HK, et al. Baseline characteristics and risk factors of retinal vein occlusion: a study by the Korean RVO Study Group. J Korean Med Sci 2013; 28: 136-144. 8.
Thapa R, Bajimaya S, Paudyal G, et al. Prevalence, pattern and risk factors of retinal vein occlusion in an elderly population in Nepal: the Bhaktapur retina study. BMC Ophthalmol 2017; 17: 162. 9.
Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol 2014; 2014: 724780. 10.
Zhao J, Sastry SM, Sperduto RD, et al. Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology 1993; 100: 423-428. 11.
Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 1999; 106: 2054-2062. 12.
Trope GE, Lowe GD, McArdle BM, et al. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 1983; 67: 137-142. 13.
O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126: 692-699. 14.
Newman-Casey PA, Stem M, Talwar N, et al. Risk factors associated with developing branch retinal vein occlusion among enrollees in a United States managed care plan. Ophthalmology 2014; 121: 1939-1948. 15.
Trope GE, Lowe GD, McArdle BM, et al. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 1983; 67: 137-142. 16.
Chen HC, Wiek J, Gupta A, et al. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998; 82: 162-167. 17.
Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963. 18.
Glueck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-49. 19.
Rehak M, Krcova V, Slavik L, et al. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol. 2010; 45: 171-175. 20.
Rothman AL, Thomas AS, Khan K, Fekrat S. Central retinal vein occlusion in young individuals: A Comparison of Risk Factors and Clinical Outcomes. Retina 2019; 39: 1917-1924. 21.
Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000; 151: 862-877. 22.
Castro R, Rivera I, Blom HJ, et al. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherit Metab Dis 2006; 29: 3-20. 23.
McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389. 24.
Wenzler EM, Rademakers AJ, Boers GH, et al. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993; 115: 162-167. 25.
Barroso M, Handy DE, Castro R. The Link Between Hyperhomocysteinemia and Hypomethylation: Implications for Cardiovascular Disease. J Inborn Errors Metab Screen 2017; 5: 2326409817698994. 26.
van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051. 27.
Wilcken B, Bamforth F, Li Z, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 2003; 40: 619-625. 28.
Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62: 1258-1260. 29.
Li D, Zhou M, Peng X, Sun H. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis. BMC Ophthalmol 2014; 14: 147. 30.
Nurk E, Tell GS, Vollset SE, et al. Changes in lifestyle and plasma total homocysteine: the Hordaland Homocysteine Study. Am J Clin Nutr 2004; 79: 812-819. 31.
Vieira MJ, Campos A, do Carmo A, et al. Thrombophilic risk factors for retinal vein occlusion. Sci Rep 2019; 9: 18972. 32.
Schockman S, Glueck CJ, Hutchins RK, et al. Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity. Clin Ophthalmol 2015; 9: 591-600. 33.
Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory markers in the diagnosis of venous thromboembolism. Circulation 2004; 109 (12 Suppl 1): I4-I8. 34.
Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134. 35.
Slavik L, Krcova V, Hlusi A, et al. Molecular pathophysiology of thrombotic states and their impact to laboratory diagnostics. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 19-25. 36.
Turello M, Pasca S, Daminato R, et al. Retinal vein occlusion: evaluation of „classic” and „emerging” risk factors and treatment. J Thromb Thrombolysis 2010; 29: 459-464. 37.
Nalcaci S, Degirmenci C, Akkin C, Mentes J. Etiological factors in young patients with Retinal Vein Occlusion. Pak J Med Sci 2019; 35: 1397-1401. 38.
Russo PD, Damante G, Pasca S, et al. Thrombophilic mutations as risk factor for retinal vein occlusion: a case-control study. Clin Appl Thromb Hemost 2015; 21: 373-377. 39.
Glueck CJ, Wang P, Bell H, et al. Associations of thrombophilia, hypofibrinolysis, and retinal vein occlusion. Clin Appl Thromb Hemost 2005; 11: 375-389. 40.
Janssen MC, den Heijer M, Cruysberg JR i wsp. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026. 41.
Zhou JQ, Xu L, Wang S, et al. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology 2013; 120: 803-808. 42.
Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111-131. 43.
Bakirci EM, Topcu S, Kalkan K, et al. The role of the nonspecific inflammatory markers in determining the anatomic extent of venous thromboembolism. Clin Appl Thromb Hemost 2015; 21: 181-185. 44.
Kim JH, Han DS, Bang HY, et al. Preoperative neutrophil-to-lymphocyte ratio is a prognostic factor for overall survival in patients with gastric cancer. Ann Surg Treat Res 2015; 89: 81-86. 45.
Asaoka T, Miyamoto A, Maeda S, et al. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology 2016; 16: 434-440. 46.
Xue TC, Jia QA, Ge NL, et al. The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. Tumour Biol 2015; 36: 6045-6051. 47.
Gursoy OM, Karakoyun S, Kalcik M, et al. Usefulness of novel hematologic inflammatory parameters to predict prosthetic mitral valve thrombosis. Am J Cardiol. 2014; 113: 860-864. 48.
Artoni A, Abbattista M, Bucciarelli P, et al. Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. Clin Appl Thromb Hemost 2018; 24: 808-814. 49.
Zhu D, Liu X. Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Branch Retinal Vein Occlusion. Hindawi J Ophthalmol 2019; 2019: 6043612. 50.
Simmons NL, Joseph A, Baumal CR. Traumatic Branch Retinal Vein Occlusion With Retinal Neovascularization Following Inadvertent Retrobulbar Needle Perforation. Ophthalmic Surg Lasers Imaging Retina 2016; 47: 191-193. 51.
Szigeti A, Schneider M, Ecsedy M, et al. Association between retinal vein occlusion, axial length and vitreous chamber depth measured by optical low coherence reflectometry. BMC Ophthalmol 2015; 15: 45. 52.
Bertelmann T, Bertelmann I, Szurman P, et al. Glaskorperstatus und retinaler Venenverschluss [Vitreous body and retinal vein occlusion]. Ophthalmologe 2014; 111: 1178-1182. 53.
Azar G, Voigt M, Al-Arabi Z, Lachkar Y. Glaucomes primitifs a angle ouvert (GPAO), occlusions veineuses retiniennes (OVR) et pachymetrie: quelle relation ? [Primary open-angle glaucoma (POAG), retinal vein occlusions (RVO) and central corneal thickness (CCT): what is the relationship?]. J Fr Ophtalmol 2013; 36: 449-454. 54.
Beaumont PE, Kang HK. Cup-to-disc ratio, intraocular pressure, and primary open-angle glaucoma in retinal venous occlusion. Ophthalmology 2002; 109: 282-286.
|
|
ENGLISH
